Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 3 HR for the Primary End Point at 2 Years Stratified by Quartiles of Baseline LDL-C
A decrease in the benefit of atorvastatin 80 mg over pravastatin 40 mg was seen from the highest to the lowest quartiles of baseline LDL-C. Treatment with atorvastatin 80 mg reduced the primary end point compared with pravastatin 40 mg in patients in the highest baseline LDL-C quartile, whereas similar outcomes were observed in the lowest quartile of baseline LDL-C. An adjusted interaction term between treatment assigned and quartile 1 versus 4 was significant (p = 0.03) for the primary end point. A = atorvastatin; HR = hazard ratio; P = pravastatin; other abbreviations as in Figure 1.
|
